Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate SYN115 in Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Parkinson's disease~* Hoen and Yahr stage 1-3~* On stable dose of anti-parkinsons treatment for 30 days prior to screening~* Age 40 to 75 years~* Sign an IRB approved informed consent~* Men and women agree to use adequate birth control~* ECG measurements are within normal limits~* Able to understand study requirements~Exclusion Criteria:~* Secondary Parkinson's (drug induced or post stroke)~* Received treatment with other investigational drug 30 days prior to study entry~* Using disallowed medications~* Significant neurological illness other than Parkinson's~* IQ less than 70 on IQ test~* MMSE score \< or = 23~* History of psychosis or on anti-psychotic medication~* Current serious medical illness~* History of substance abuse~* History of head injury with loss of consciousness~* History of brain surgery~* Contraindications to MRI like claustrophobia, metal implants or other implantable devices~* Abnormal liver function tests and/or hepatitis or cholangitis~* Gilberts disease~* Pregnant or nursing~* Known hypersensitivity to SYN115

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Active medication Tozadenant 20 mg oral capsules with a daily dosage of either 20 mg BID or 60 mg BID
- 2 (Type: PLACEBO_COMPARATOR): Crossover from arm 1 to arm 2 with one week washout. One of the arms is placebo control

Based on this trial design, predict the completion outcome and termination type (if applicable).